Compounded medication for patients with rare diseases
Abstract Background When there is no authorized on- or in absence even no off-label treatment for patients with rare diseases, pharmacists have to compound medicinal products to meet the patients special needs. However it is important that there is evidence in the medical and/or pharmaceutical liter...
Main Authors: | Marc Dooms, Maria Carvalho |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-01-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-017-0741-y |
Similar Items
-
A Drug Content, Stability Analysis, and Qualitative Assessment of Pharmacists’ Opinions of Two Exemplar Extemporaneous Formulations
by: Melissa Kirkby, et al.
Published: (2020-07-01) -
Orphan Drugs, Compounded Medication and Pharmaceutical Commons
by: Kim Hendrickx, et al.
Published: (2021-09-01) -
Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases
by: V. Vanhoorne, et al.
Published: (2019-08-01) -
Off-label use of orphan medicinal products: a Belgian qualitative study
by: Marc Dooms, et al.
Published: (2016-10-01) -
Analysis and expansion ways of the extemporaneous preparations assortment in the republic of Tajikistan
by: Абдуджаббор Халкуллоевич Валиев, et al.
Published: (2015-11-01)